CD123/CLL1 CAR-T Cells for R/R AML (STPHI_0001)

CD123/CLL1 CAR-T Cell Therapy for Relapsed and Refractory Acute Myeloid Leukemia

The treatment options for relapse/refractory B-cell acute myeloid leukemia(AML)are limited.CD123/CLL1 CAR-T Cells may have a permanent anti-tumor effect and became very attractive. This study aims to assess the safety and toxicity of CD123/CLL1 CAR-T Cells to patients with relapse/refractory AML.

Inclusion Criteria:

• Signed written informed consent
• Aged < 70 years
• Patients with relapsed/refractory AML
• Cardiac: Left ventricular ejection fraction ≥ 50%
• Adequate renal and hepatic function
• Performance status: Karnofsky ≥ 70%

Exclusion Criteria:

• Pregnant or lactating females.
• Any co-morbidity precluding the administration of CD123/CLL1 CAR-T Cells.